Previous 10 |
EMERYVILLE, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Mike Forcht, Ed.D., M.B.A., has joined the com...
Chiasma (NASDAQ: CHMA ) initiated with Overweight rating and $18 (208% upside) price target. Shares up 3% premarket. More news on: Chiasma, Mylan Inc, Teva Pharmaceutical Industries Limited, Healthcare stocks news, Stocks on the move, Read more ...
EMERYVILLE, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president...
-- MHC Class II Antigen Prediction by Gritstone’s Proprietary Artificial Intelligence Platform EDGE TM Shows Significant Improvement Over Standard Prediction Tools -- -- EDGE Enables Identification of Neo...
EMERYVILLE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Jean-Marc Bellemin, M.B.A., executive vice presid...
Quick Take TCR2 Therapeutics ( TCRR ) intends to raise gross proceeds of $75 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing therapies that harness the patient's immune system to fight cancer irrespective of human leukocyte antigens [HLA] sub...
Gritstone Oncology ( GRTS ) is one of my top picks for 2019. The stock doubled to about $30/share since the IPO and then was cut in half due to the broad market sell off. Shares have rebounded over past two weeks as the broad market has recovered. The company will release phase 2 data from GRA...
News, Short Squeeze, Breakout and More Instantly...
Gritstone Oncology Inc. Company Name:
GRTS Stock Symbol:
NASDAQ Market:
Gritstone Oncology Inc. Website:
-- Event will feature Dr. Randolph Hecht (Professor, UCLA GI Oncology Program) and Howard Brown (CRC Survivor, Patient and Advocate) -- EMERYVILLE, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the...
2024-06-14 13:15:03 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for GRTS on June 14, 2024 11:01AM ET. The previous analyst recommendation was Market Outperform. GRTS was trading at $0.7575 at issue of the analyst recommendation. The overall analyst ...
2024-05-24 11:30:04 ET B. Riley analyst issues BUY recommendation for GRTS on May 24, 2024 09:31AM ET. The previous analyst recommendation was Buy. GRTS was trading at $0.8039 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...